COCP and Breast Cancer Risk

Current or recent use of combined oral contraceptive pills (COCPs) is associated with a small but measurable increase in breast cancer risk, with a relative risk of approximately 1.2-1.6 for current users, though this risk disappears within 10 years of discontinuation 1, 2

Magnitude of Risk for Current/Recent Users

Current users have a relative risk of 1.24 (95% CI, 1.15-1.33) based on a large meta-analysis of 53,297 women with breast cancer and 100,239 controls 1, 2
More recent systematic reviews show a relative risk of 1.08 (95% CI, 1.00-1.17) for current COCP users 1, 2

The elevated risk disappears completely within 10 years after discontinuation 1, 2
This temporal pattern suggests the risk is related to active hormonal exposure rather than a permanent carcinogenic effect 1, 2

Women under 34 years have the highest relative risk increase, though their baseline breast cancer incidence remains very low 1, 2
The absolute risk remains low even with these elevated relative risks due to the rarity of breast cancer in young women 1, 2

Current evidence does not suggest that increased baseline risk for breast cancer among women with family history or BRCA1/2 genes is modified by COCP use 3, 4, 5

Current breast cancer is Category 4 (unacceptable health risk) because breast cancer is a hormonally sensitive tumor and prognosis may worsen with hormonal contraceptive use 3, 4, 5, 6
Past breast cancer with no evidence of disease for 5 years is Category 3 (theoretical or proven risks usually outweigh advantages) 3, 4, 5

Exclude absolute contraindications: Current or recent (<5 years) breast cancer diagnosis 3, 4, 5
Evaluate cardiovascular risk factors: Age ≥35 with smoking, hypertension, diabetes, or other cardiovascular disease significantly increases VTE, MI, and stroke risk beyond breast cancer concerns 1, 2

Do not overestimate absolute risk in young women: A relative risk of 1.5 in a 25-year-old translates to minimal absolute risk increase given the rarity of breast cancer at that age 1, 2
Do not assume past COCP use permanently increases risk: The risk elevation is confined to current/recent use and resolves within 10 years of stopping 1, 2
Do not unnecessarily restrict COCPs in women with family history: Evidence does not support significantly amplified risk in this population 3, 4, 5
Do not prescribe COCPs solely for acne without contraceptive need: FDA approval requires concurrent desire for contraception 1, 2

Women with a family history of breast cancer do not appear to have a significantly higher risk of breast cancer with oral contraceptive use compared to women without such history, as recommended by the Centers for Disease Control and Prevention 7, 8
For carriers of BRCA1/2 genetic mutations, the National Comprehensive Cancer Network indicates that studies have shown conflicting results, with some showing increased risk and others showing no significant association 9, 10
The American Academy of Dermatology notes that the risk of breast cancer is greatest in women under 34 years of age, when the overall incidence of breast cancer is at its lowest 11

The National Comprehensive Cancer Network recommends that oral contraceptive use significantly reduces ovarian cancer risk by approximately 50% 9, 10
The Centers for Disease Control and Prevention states that oral contraceptive use is also associated with reduced risk of endometrial cancer 7
The American Academy of Family Physicians suggests that colorectal cancer risk may be reduced by about 20% among women who have ever used hormonal replacement therapy, with potentially similar benefits for hormonal contraception 12, 13

For women over 40, the American College of Obstetricians and Gynecologists classifies non-hormonal methods (copper IUD) or progestin-only methods as Category 1 (no restrictions) 14, 15
The American College of Obstetricians and Gynecologists classifies combined hormonal contraceptives as Category 2 (benefits generally outweigh risks) for women ≥40 years without other risk factors 14, 15
The American College of Obstetricians and Gynecologists notes that combined hormonal contraceptives are contraindicated (Category 4) in smokers aged ≥35 years due to increased cardiovascular risks 14, 15

The Journal of the American Academy of Dermatology reports that the risk of venous thromboembolism (VTE) is higher among oral contraceptive users than non-users, with baseline risk of 3-9 per 10,000 woman-years compared to 1-5 per 10,000 woman-years in non-users 11
The American Heart Association indicates that cardiovascular risks (myocardial infarction, stroke) are increased with hormonal contraceptive use, particularly in women with additional risk factors such as smoking, diabetes, and hypertension 11

Women using oral contraceptives for more than 5 years show relative risks of 1.33-1.56, according to the National Comprehensive Cancer Network 16, 17

The National Comprehensive Cancer Network states that oral contraceptive use is acceptable for contraception in BRCA carriers, with the risk/benefit ratio uncertain due to contradictory evidence 18
Meta-analyses show no significant association between oral contraceptive use and breast cancer risk in BRCA1/2 carriers 16, 17
One case-control study found modest increased risk in BRCA1 carriers (OR 1.20) with 5 or more years of use, particularly before age 40 (OR 1.38) 16, 17
Another study found increased risk in BRCA2 carriers with 5 or more years of use (OR 2.06) 16, 17
Conversely, one study found low-dose oral contraceptives decreased breast cancer risk in BRCA1 carriers (OR 0.22) 16, 17
Oral contraceptives reduce ovarian cancer risk by 45-60% in BRCA1/2 carriers, with risk decreasing further with longer duration of use 16, 17

For women with family history or BRCA mutations, provide genetic counseling and testing if not already done, and consider low-dose formulations which may have more favorable risk profiles 16, 17

The American College of Obstetricians and Gynecologists notes that oral contraceptive pills provide substantial ovarian cancer risk reduction of 40-60%, which is particularly important for BRCA1/2 carriers who face high ovarian cancer risk 19, 20
The ovarian cancer risk reduction benefit increases with longer duration of use and persists long after discontinuation, as recommended by the National Comprehensive Cancer Network 19, 20

The American Society of Clinical Oncology suggests that for confirmed BRCA1/2 carriers, oral contraceptive pills are acceptable for contraception given the substantial ovarian cancer risk reduction and lack of consistent evidence for increased breast cancer risk 19, 20
The World Health Organization highlights the 40-60% ovarian cancer risk reduction, which is permanent and increases with duration of use, as a key consideration in the risk-benefit balance of oral contraceptive pill use 19, 20